Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Non-Current Liabilities: 2015-2025

Historic Total Non-Current Liabilities for Aytu Biopharma (AYTU) over the last 11 years, with Jun 2025 value amounting to $42.1 million.

  • Aytu Biopharma's Total Non-Current Liabilities rose 44.73% to $35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.8 million, marking a year-over-year increase of 44.73%. This contributed to the annual value of $42.1 million for FY2025, which is 49.72% up from last year.
  • According to the latest figures from FY2025, Aytu Biopharma's Total Non-Current Liabilities is $42.1 million, which was up 49.72% from $28.2 million recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's Total Non-Current Liabilities ranged from a high of $109.6 million in FY2021 and a low of $28.1 million during FY2023.
  • In the last 3 years, Aytu Biopharma's Total Non-Current Liabilities had a median value of $28.2 million in 2024 and averaged $32.8 million.
  • As far as peak fluctuations go, Aytu Biopharma's Total Non-Current Liabilities surged by 141.43% in 2021, and later tumbled by 65.11% in 2023.
  • Aytu Biopharma's Total Non-Current Liabilities (Yearly) stood at $109.6 million in 2021, then decreased by 26.55% to $80.5 million in 2022, then plummeted by 65.11% to $28.1 million in 2023, then rose by 0.21% to $28.2 million in 2024, then soared by 49.72% to $42.1 million in 2025.